v3.26.1
Exclusive Option Agreement and Collaboration Agreements - Additional Information (Details) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Nov. 03, 2025
Dec. 31, 2025
Oct. 31, 2025
Aug. 31, 2025
Jun. 30, 2026
Jun. 30, 2026
Dec. 31, 2025
Exlcusive Option Agreement              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Performance obligation revenue recognised         $ 5,700,000 $ 10,300,000  
Amended Research Collaboration Agreement              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Upfront, non-refundable fee       $ 6,500,000      
Expanded License Agreement              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Upfront Payment             $ 6,000,000
Upfront, non-refundable fee     $ 6,000,000        
Deferred revenue recognized         0 0  
Deferred upfront payment         $ 3,000,000 3,000,000  
Incyte Corporation              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Share price $ 3.98            
Share premium paid per share             $ 0.02
Total share premium paid             $ 100,000
Gross equity proceeds from issuance of common stock             24,900,000
Incyte Corporation | Asset Purchase Agreement              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Option to acquire agreement amount $ 100,000,000            
Incyte Corporation | Asset Purchase Agreement | Maximum              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Net sales on additional clinical and regulatory milestones, and single digit royalties 775,000,000            
Net potential cash payment 910,000,000            
Incyte Corporation | Exlcusive Option Agreement              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Initial upfront payment received in cash $ 35,000,000            
Transaction price             35,100,000
Upfront payment and equity premium   $ 35,000,000         35,000,000
Research and development performance obligations   $ 35,100,000         $ 35,100,000
Upfront Payment           $ 22,200,000  
Incyte Corporation | Securities Purchase Agreement | Voting shares              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Shares sold   4,372,124          
Incyte Corporation | Securities Purchase Agreement | Non-voting Common Stock              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Shares sold 6,250,000            
Shares issued price per share $ 4            
Issuance of common stock and prefunded warrants, net of issuance costs of $4,556.5 thousand $ 25,000,000